Spondyloarthritis & psoriatic arthritis
Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study
Authors' conclusion
IV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks.
Study context
- Population
- Adults with active axial spondyloarthritis (axSpA) (either radiographic or nonradiographic)
- Participants
- 264 vs 262
- Comparison
- Intravenous (IV) secukinumab vs IV placebo for 16 weeks
- Secukinumabn = 264
- Placebon = 262reference
- Primary endpoint
- ASAS40 response
- Follow-up
- Week 16
Methodological detailsdouble-blind, parallel-group, phase 3
- Double-blind
- Parallel-group
- Phase 3
Primary result
As reported in the abstract
P < 0.0001
Secondary outcomes
Completed the entire 60-week study period
ASAS40 response after switch from placebo to secukinumab at week 16 · week 24
- Response rates comparable to those originally randomised to secukinumab
Secondary efficacy endpoints · week 16
- All secondary efficacy endpoints were met at week 16, and responses were sustained through week 52
Original publication
Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study. Arthritis Rheumatol. Published 31 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →